Identifying biomarkers for diagnosing and predicting outcomes in NAFLD
Identification of New Biomarkers in the Diagnosis and Prognosis of Non-alcoholic Fatty Liver Disease and Correlation With Ultrasound and Elastographic Findings
This study is trying to find new blood tests that can help doctors diagnose and predict outcomes for people with non-alcoholic fatty liver disease, especially those who are obese.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | University of Trieste Academic / other |
| Locations | 1 site (Trieste) |
| Trial ID | NCT06098417 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify potential biomarkers that can aid in the diagnosis and prognosis of non-alcoholic fatty liver disease (NAFLD), particularly focusing on patients with obesity. The research will utilize non-invasive methods such as plasma tests and liver elastography, as current diagnostic practices rely heavily on liver biopsy, which is not feasible for all patients. The study will analyze the relationship between lifestyle factors, obesity, and the progression of liver fibrosis in individuals at risk for chronic liver diseases. By developing a better understanding of these biomarkers, the study seeks to improve early detection and management of NAFLD.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with a BMI greater than 35 who are eligible for bariatric surgery.
Not a fit: Patients with active liver viral infections, those with alcohol or drug addiction, and incompetent patients may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to non-invasive diagnostic tools that improve early detection and management of NAFLD, potentially reducing the need for liver biopsies.
How similar studies have performed: While there have been studies exploring biomarkers in liver diseases, this approach focusing specifically on NAFLD and obesity is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: BMI\> 35 Eligible for bariatric surgery according to the current international guidelines (IFSO guidelines) Exclusion Criteria: * Patients affected by active liver viral infection * Patient alcohol or drug addicted * Incompetent patients
Where this trial is running
Trieste
- Silvia Palmisano — Trieste, Italy (Recruiting)
Study contacts
- Study coordinator: Silvia Palmisano, MD
- Email: spalmisano@units.it
- Phone: 0403994152
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.